May 7th 2024
There was a statistically significant reduction in average daily micturition episodes and average daily urgency episodes with vibegron vs placebo.
UGN-102 treatment leads to meaningful DFS outcomes in NMIBC, regardless of prior TURBT
A post hoc analysis of the phase 3 ATLAS trial showed that UGN-102 with or without TURBT induced meaningful disease-free survival and duration of response in patients with non–muscle-invasive bladder cancer.
Novel gene therapy EG-70 nears 75% complete response rate in NMIBC
EG-70 is an experimental intravesical immunotherapy that does not involve viruses or integration. It aims to eliminate tumors by triggering coordinated innate and adaptive immune reactions specifically within the bladder.
Enzalutamide regimens increase undetectable PSA likelihood in nonmetastatic CSPC
More patients with nonmetastatic castration-sensitive prostate cancer reached an undetectable PSA level if they received enzalutamide, as a single agent or combined with leuprolide, vs if they received leuprolide alone.
Steerable ureteroscopic renal evacuation shows promise for kidney stone removal
May 4th 2024Steerable ureteroscopic renal evacuation using the CVAC Aspiration System demonstrated noninferiority vs standard ureteroscopy for kidney stone removal, according to findings from the prospective, randomized ASPIRE trial.
TAR-200 sustains impressive clinical activity in BCG-unresponsive NMIBC
Treatment with the intravesical gemcitabine delivery system TAR-200 led to complete responses in over 80% of patients with BCG-unresponsive, high-risk non–muscle-invasive bladder cancer, according to the latest results from the phase 2b SUNRISE-1 trial.
Cretostimogene grenadenorepvec reaches high complete response rate in NMIBC
The novel oncolytic immunotherapy cretostimogene grenadenorepvec induced complete responses in three-fourths of patients with BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ, according to findings from the phase 3 BOND-003 trial.
Expert discusses novel approach to ctDNA detection in MIBC
May 2nd 2024"[This] shows a different approach for detecting circulating tumor DNA in bladder cancer patients, and it opens up the possibility for other biorepositories that have serum samples to also enter the ctDNA research environment," says Richard T. Bryan, MBChB, PhD, MRCS, FacadTM.